Experimental bladder cancer treatment for early-stage, BCG-unresponsive disease
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This phase 1 trial tests a new treatment for early-stage bladder cancer that has not responded to BCG therapy. The treatment is given directly into the bladder (intravesical), which may help avoid removing the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your bladder cancer must be the type called carcinoma in situ (CIS) or early-stage bladder cancer that has not spread into the muscle layer.
- You must have received BCG treatment before, and your cancer either came back or didn't go away after that treatment.
- You must not be able to have surgery to remove your bladder, or you must refuse that surgery.
- You must be expected to live at least 2 more years and be in reasonably good health.
- You must have no other cancer in the last 3 years, except for certain skin cancers or non-invasive cervical cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a combination of an immunotherapy drug (toripalimab) with or without two chemotherapy drugs placed directly into the bladder (gemcitabine and mitomycin C). It is for people whose high-risk bladder cancer did not respond to or could not tolerate BCG treatment.
This trial tests a new treatment for bladder cancer that does not respond to standard BCG therapy. The treatment uses tiny particles (micelles) that deliver a chemotherapy drug directly into the bladder, aiming to destroy cancer cells without needing surgery.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.